Starling Oncology, Inc.
DFPH- Exchange
- OTC
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- SEC CIK
- 0001799191
In the last 90 days, Starling Oncology, Inc. insiders filed 2 open-market purchases and 2 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:59 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $60.6M (12.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 24, 2025 | Mar 27, 2024 | Mar 9, 2023 | Mar 10, 2022 |
| Revenue | $502.7M | $393.4M | $324.2M | $252.5M | $203.0M |
| Selling, general and administrative | $105.6M | $107.8M | $113.9M | $119.7M | $83.4M |
| Operating income | -$36.1M | -$60.1M | -$77.0M | -$82.0M | -$45.9M |
| Interest expense | – | – | – | – | $320.0K |
| Income tax | -$131.0K | $0 | -$36.0K | -$243.0K | -$671.0K |
| Net income | -$60.6M | -$64.7M | -$83.1M | $152.0K | -$10.9M |
| EPS, basic | $-0.54 | $-0.71 | $-0.92 | $0.00 | $-0.16 |
| EPS, diluted | $-0.54 | $-0.71 | $-0.92 | $-0.21 | $-0.16 |
| Weighted shares, basic | 92.4M | 75.0M | 73.7M | 72.8M | 66.2M |
| Weighted shares, diluted | 92.4M | 75.0M | 73.7M | 80.6M | 66.2M |
| Margins and growth | |||||
| Operating margin | -7.2% | -15.3% | -23.8% | -32.5% | -22.6% |
| Net margin | -12.1% | -16.4% | -25.6% | 0.1% | -5.4% |
| Revenue growth, year over year | +27.8% | +21.3% | +28.4% | +24.4% | – |
| Net income growth, year over year | – | – | −54,750.0% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 24, 2025 | Mar 27, 2024 | Mar 9, 2023 | Mar 10, 2022 |
| Short-term investments | – | $0 | $49.4M | $59.8M | – |
| Accounts receivable | $59.0M | $48.3M | $42.4M | $39.8M | $20.0M |
| Inventory | $16.9M | $10.0M | $13.7M | $9.26M | $6.44M |
| Total current assets | $112.7M | $112.4M | $143.5M | $130.4M | $154.1M |
| Property, plant and equipment | $10.7M | $11.9M | $10.9M | $8.55M | $4.19M |
| Goodwill | $7.23M | $7.23M | $7.23M | $21.4M | $26.6M |
| Intangible assets | $11.0M | $14.8M | $17.9M | $18.0M | $18.2M |
| Total assets | $164.7M | $172.7M | $209.2M | $261.7M | $203.4M |
| Accounts payable | $43.2M | $24.3M | $14.4M | $9.37M | $15.6M |
| Short-term debt | – | – | – | $0 | $183.0K |
| Total current liabilities | $71.0M | $52.2M | $34.8M | $29.7M | $29.8M |
| Long-term debt | $77.4M | $93.1M | $86.8M | $80.6M | $0 |
| Total liabilities | $180.4M | $169.1M | $152.2M | $138.5M | $99.3M |
| Shareholders' equity | -$15.7M | $3.59M | $57.0M | $123.2M | $104.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 24, 2025 | Mar 27, 2024 | Mar 9, 2023 | Mar 10, 2022 |
| Operating cash flow | -$24.6M | -$26.5M | -$36.3M | -$61.8M | -$32.7M |
| Capital expenditures | $3.20M | $3.79M | $4.57M | $5.53M | $2.85M |
| Free cash flow | -$27.8M | -$30.3M | -$40.9M | -$67.3M | -$35.5M |
| Depreciation and amortization | $6.94M | $6.29M | $5.87M | $4.41M | $3.34M |
| Stock-based compensation | $4.55M | $11.2M | $17.8M | $27.7M | $24.5M |
| Share buybacks | – | $0 | $1.02M | $9.00M | – |
| Investing cash flow | -$3.07M | $46.2M | $62.6M | -$131.6M | -$12.2M |
| Financing cash flow | $11.6M | -$3.49M | -$6.85M | $92.2M | $154.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 0.9% | 2.8% | 5.5% | 11.0% | 12.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2026 | 102.0M | +3.7% | SEC |
| Jul 30, 2026 | 101.9M | +9.0% | SEC |
| Apr 30, 2026 | 100.0M | +12.0% | SEC |
| Mar 5, 2026 | 98.8M | +30.5% | SEC |
| Nov 6, 2025 | 98.4M | +30.2% | SEC |
| Aug 6, 2025 | 93.5M | +23.9% | SEC |
| May 7, 2025 | 89.2M | +19.9% | SEC |
| Mar 10, 2025 | 75.8M | +1.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.